Alerta

用于APOE ε3/ε3基因型个体阿尔茨海默病的生物标志物组合

Resumen de: CN122525140A

0001 本发明涉及生物标志物组合在制备用于APOE ε3/ε3基因型个体阿尔茨海默病的检测试剂盒中的应用，所述的生物标志物选自ANGPTL1，PON2，PTN，SCGB3A1，PBLD，MORC3，EIF5A，FAM3D，PIKFYVE，CKB，HGF，TREH，GSTA3，EIF2AK3，CTSD，FOLH1中的至少一种，实现了在该人群中对阿尔茨海默病高精度、高特异性的体外诊断。

一种抗β-淀粉样前体蛋白的抗体及其相关产品和应用

Resumen de: CN122520771A

0001 本发明公开了一种抗β‑淀粉样前体蛋白的抗体及其相关产品和应用，所述抗体可特异性结合β‑淀粉样前体蛋白，具有高亲和力和特异性，所述相关产品包括包含所述抗体的检测试剂盒、检测试剂，可用于β‑淀粉样前体蛋白的检测或β‑淀粉样前体蛋白相关疾病（如：阿尔茨海默病、轻度认知障碍、淀粉样变性相关神经退行性疾病）的诊断或辅助诊断，为临床诊疗提供可靠的分子检测依据。

一种磷酸化Tau217蛋白测定试剂盒及应用

Resumen de: CN122525131A

本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau217蛋白测定试剂盒及应用，本申请所述的磷酸化Tau217蛋白测定试剂盒包括特定的抗试剂A、抗试剂B和磁微粒试剂，所述的生物素标记的p‑Tau 217抗体与碱性磷酸酶标记的p‑Tau 217抗体反应生成，抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的特异性结合反应结合到磁性微粒上，能够有效的降低检测限，实现了磷酸化Tau217蛋白的高灵敏度检测，空白限不高于0.20pg/mL，且在0.50pg/mL~50.00pg/mL范围内线性相关性好（r≥0.9900），可实现磷酸化Tau217蛋白的准确定量。

METHOD FOR IDENTIFYING A MULTI-PARAMETER PHENOTYPE OF MICROBIOTA

Resumen de: US20260227396A1

0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.

脳脊髄液に含まれるＨｅｘ４の定量法

Resumen de: WO2021039644A1

The present invention addresses the problem of providing a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide in a brain. The present invention relates to a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide included in a cerebrospinal fluid, the method comprising: a step for adding an internal standard substance to a solution containing the cerebrospinal fluid; a step for subjecting the solution, which contains the cerebrospinal fluid and to which the internal standard substance is added, to liquid chromatography to obtain an effluent; and a step for providing the effluent for mass spectrometry.

Systems and Methods for the Prediction of Post-Operative Cognitive Decline Using Blood-Based Inflammatory Biomarkers

Resumen de: US20260229316A1

Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.

COMPOSITIONS INCLUDING ANTI-WT-1 ANTIBODIES & ANTIGEN BINDING FRAGMENTS AND USES THEREOF

Resumen de: US20260226173A1

The present technology relates generally to compositions that specifically recognize and bind to a WT-1 peptide complexed with a major histocompatibility antigen (e.g., HL A-A*02). The compositions of the present technology are useful in methods for treating WT-1-associated diseases (e.g., cancers) in a subject in need thereof.

ENHANCEMENT OF SYNAPTOGENESIS BY ACTIVATION OF TENEURINS

Resumen de: US20260224661A1

Methods are provided for enhancing synaptogenesis. It is shown herein that the receptor for the circulating factor SPARCL1 (secreted protein acidic and rich in cysteine-like protein) are teneurin proteins (Tenm1-4). The binding site for SPARCL1 is localized to domain 3, which specifically binds to the C terminal domain of SPARCL1 (SPARCL1-C). Contacting neuronal cells expressing a teneurin protein with SPARC is sufficient to increase synapse formation on the neuronal cells.

Methods of Treating Neurological Disorders with Anti-Abeta Antibodies

Resumen de: US20260226143A1

0000 Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

IDENTIFICATION OF THE PROTEINS ELASTASE 3B AND IGKAPPA CHAIN AS FECAL BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER' S DISEASE

Resumen de: WO2026163093A1

Two proteins, Elastase 3B and igKappa chain, are identified as biomarkers for the diagnosis and prognosis of Alzheimer's disease (Alzheimer Disease, AD). These proteins can be detected in fecal samples from subjects affected by this pathology and exhibit a statistically significant variation in samples from AD subjects compared with the levels detected in a healthy reference sample, thereby making it possible to provide both diagnosis and prognosis of AD in a simple and non-invasive manner, in particular, Elastase 3B and igKappa chain emerge as complementary biomarkers with opposite and progressive modulation. Specifically, Elastase 3B decreases in all phases of the pathology, whereas igKappa chain shows a progressive increase that reflects the progression of AD. The combined use of these two proteins as complementary biomarkers is therefore applicable for the early diagnosis and prognosis of AD. To achieve this objective, a strategy based on the use of a preclinical model was adopted, namely the triple-transgenic murine model (3xTg-AD), which mimics the AD pathology observed in humans and reproduces its characteristics and different stages. Based on the premise that the results obtained may also be predictive for humans, the use > of the murine model offers an important advantage, namely the possibility of collecting samples to be analyzed at precise time points, thereby allowing the study of the pathology in its different stages, from the asymptomatic phase to the early sym

METHODS PERTAINING TO NEURODEGENERATIVE DISEASE

Resumen de: WO2026165150A2

Disclosed herein are methods pertaining to analyzing a biological sample from a subject for a neurodegenerative disease. In one aspect, the disclosure relates to a method for analyzing a biological sample from a subject for a neurodegenerative disease. This method involves determining a ratio of pTau217 to BD-Tau present in a biological sample obtained from a subject and diagnosing the subject as (i) having Alzheimer's disease when the ratio of pTau217 to BD-Tau in the sample is a at least a first predetermined value; (ii) a healthy subject (no neurodegenerative disease) when the ratio of pTau217 to BD-Tau in the sample is below a second predetermined value; and/or (iii) having a disease other than Alzheimer's disease associated with high levels of pTau217 when the ratio of pTau217 to BD-Tau in the sample is between the second predetermined value and the first predetermined value.

METHOD FOR MODULATING SPLICING OF SIRTUIN 1

Resumen de: WO2026165098A1

A method for modulating splicing of Sirtuin 1 includes administering or adding to a subject 3-methyl-1-phenyl-2-pyrazolin-5-one, a physiologically acceptable salt thereof, a hydrate thereof, and/or a solvate thereof.

METHODS OF USING KISSPEPTIN OR KISSPEPTIN ANALOGS OR PHARMACEUTICAL COMPOSITIONS

Resumen de: WO2026165222A2

The invention features methods of treating a subject having a disorder by administering to the subject a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Disorders that may be treated by the kisspeptin analogs or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition include reproductive disorders, hypoactive sexual arousal disorder, respiratory diseases, metabolic disorders, liver disorders, bone disorders, VMS, neurodegenerative disorders, and sequelae of neurotropic viruses. Also provided herein are methods of identifying a subject as having congenital hypogonadotropic hypogonadism (HH) and methods of determining whether a patient having a disorder is likely to respond to a therapy comprising a therapeutically effective amount of a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

CALIBRATOR DIPEPTIDE FOR PHOSPHORYLATED TAU (P-TAU) 217 IMMUNOASSAYS

Resumen de: WO2026164954A1

The presently claimed and described technology provides a calibrator dipeptide for use in immunoassay methods for detecting phosphorylated tau (p-tau)217.

CORRECTING NOVA-ASSOCIATED HUMAN NEUROLOGICAL DISORDERS

Resumen de: WO2026165496A1

The invention relates to methods of altering expression or activity of NOVA 1 or NOVA2. The invention provides anti-microRNA molecules directed against miRNA binding sites on untranslated regions that serve to redirect RNA translation, including acting as a competitor for miRNA binding on targets, including NOVA1 and NOVA2. The invention provides methods for inhibiting microRNAs directed to NOVA1 or NOVA 1 in an animal by administering one of more anti-microRNA molecule specific therefore. Methods of alleviating one or more disease or condition, including altering or modulating vocalization, language dysfunction, autism (including non-verbal autism), microencephaly, seizures, developmental delay or cancer are provided. In accordance with such methods, NOVA1 or NOVA2 expression or activity is modulated to result in alleviation of one or more disease or condition.

CAPTURE OF MISFOLDED PROTEIN AGGREGATES BY BEADS BOUND TO AN AMYLOID-BINDING DYE.

Resumen de: WO2026165436A1

Methods are provided for the capture of misfolded protein aggregates by beads bound to an amyloid-binding dye. Methods for using the misfolded protein aggregate-bound beads are also provided.

DEVICE FOR MEASURING LIQUID VISCOSITY

Resumen de: WO2026162924A1

The disclosure relates to a device for measuring liquid viscosity wherein said device comprises a concave reservoir configured to hold a volume of liquid and one or more wells extending from an opening disposed at the base of said reservoir, wherein said base comprises an aperture having dimensions configured to retain within said well a liquid having a viscosity at or above a specific threshold viscosity by surface tension, but permit a liquid having a viscosity below said specific threshold viscosity to pass through said well under the influence of gravity. Further, the invention also relates to a method for assessing liquid viscosity using the abovementioned device, particularly in individuals suffering from dysphagia in healthcare facilities, such as care homes.

C-PEPTIDE-INSULIN FORMULATION AND METHOD FOR USE OF SAME

Resumen de: WO2026161967A1

A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.

BIOMARKERS RELATED TO IMMUNOTHERAPY EFFICACY

Resumen de: US20260224626A1

0000 The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient following treatment of the patient with an immunotherapy product, and methods for improving efficacy of an immunotherapy product for a patient with a likelihood of a relapse to a cancer following treatment with an immunotherapy product.

ANTIBODIES FOR TREATING NEUROLOGICAL AND NEUROVASCULAR DISORDERS

Resumen de: US20260226177A1

0000 The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson's disease, and others.

MULTIPLEXED ASSAY AND METHODS OF USE THEREOF

Resumen de: WO2020146652A1

The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.

TETZ-PROTEINS AND PRION-LIKE PROTEINS AND ASSOCIATED METHODS

Resumen de: US20260227416A1

0000 The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.

MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION

Resumen de: US20260226658A1

0000 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF

Resumen de: US20260226172A1

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Compositions and Methods for Modulation of Immune Responses

Nº publicación: US20260227408A1 06/08/2026

Solicitante:

FLAGSHIP PIONEERING INNOVATIONS VI LLC [US]
Flagship Pioneering Innovations VI, LLC

Resumen de: US20260227408A1

0000 The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.